JAMA · 1989 · 56 citations · 39 references
MedicineHematologyInfectious DiseasesHemostasisMolecular VirologyTransfusion MedicineBlood Component TherapyBlood Product ManagementCoagulation DisordersCoagulation Factor DeficienciesCoagulation PhysiologyTransfusion-transmitted InfectionsBlood Product UtilizationBlood-borne VirusesCoagulation Factor ConcentratesCoagulation Factor Replacement TherapyInfectious Disease EconomicsProthrombin Complex Concentrate UseViral InactivationViral Transmission Dynamics
Treatment of hemophilia, although greatly improved in recent years, continues to be problematic owing to infectious complications of blood product replacement therapy. This report examines the therapeutic options presently available for the treatment of hemophilia, focusing on the potential for repeated viral exposure to influence the progression of infectious disease, decreased risks of viral transmission with blood products produced using newer viral inactivation procedures, higher economic costs of newer blood products, and the current inadequate supply of blood products in the United States.
39
Cytokine-Induced Expression of HIV-1 in a Chronically Infected Promonocyte Cell Line
Thomas M. Folks, J. Shawn Justement, Audrey Kinter et al. · Science · 1987 · 925 citations